Bioverse Episode 10 - Recap of ASCO2024 & BI02024

汇聚群英智慧，闪亮你我星光

Together, Spark Biomedicine!

In Bioverse Episode 10, Madeleine Armstrong from OncologyPipeline and Ramon Valencia from Seacross Pharmaceuticals will join co-hosts Angus Liu from Fierce Pharma and Leon Tang from InScienceWeTrust BioAdvisory to discuss the winners, losers, and black horses from ASCO 2024 and BIO 2024.

All our speakers will attend ASCO or BIO in person, and they will share the highlights of the latest breakthroughs in clinical oncology presented at ASCO2024 and the industry-shaping deals announced at BIO2024.

Event details

主题：BioVerse episode 10 - Recap of ASCO2024 & BI02024：The Winners, Losers, and Dark Horses

时间: 2024年6月6日 Thur 9:00 AM（EST）/ 2024年6月6日 周四  9:00 PM（北京时间）

地点: zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）

Speakers intro

Madeleine Armstrong

Madeleine has over 16 years’ experience writing about the biopharma and medtech industries. She joined ApexOnco in 2023 after eight years at Evaluate Vantage, most recently as News Editor. Before that, she was Deputy Editor of Clinica, a medical device publication, and has also worked for Scrip as a reporter.

Ramon Valencia

Ramon currently serves as VP, Head of Global Business Development and Strategic Collaborations with Seacross Pharmaceuticals USA Inc. where he is responsible for establishing strategic partnerships and collaborations with the pharmaceutical industry.  Prior to that he was the VP of BD for SystImmune where he led deal structuring and negotiations for the $8.4B global strategic collaboration between BMS and SystImmune for BL-B01D1.  With over 25 years of experience in the biotech pharma industry and having worked as a researcher for over 12 years, Ramon holds multiple patents in medical diagnostics and wearable electronic devices and excels in developing strategic partnerships with renowned institutions and pharmaceutical companies. Throughout his career, he has held key positions in biotech/pharma, drug discovery and development companies, contributing to their growth and success.  Prior to joining SystImmune, Ramon was the Head of Business Development at Conagen Pharmaceutical Division where he in-licensed a novel HER2 targeting antibody as well as an ADC platform for clinical development.  Prior to that, he was the Head of Corporate Development at AvantGen, Vice President of Corporate Development and Strategy at Zumutor Biologics, among others.  Ramon has Master of Science in Biology from California State University, was an NIH Research Fellow at the Department of Biochemistry, University of Oxford, U.K. and has succeeded the Effective Negotiations and Power of Persuasion Program from USC Marshall School of Business.

Angus Liu

(Co-host)

Angus Liu is a deputy editor at Fierce Pharma, the go-to destination for the news and trends shaping the pharma industry. He leads the publication’s oncology coverage.

Leon ‘Jun’ Tang

(BioVerse webinar host)

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.

Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.

Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.

Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center. 

Organizer

Partner &Collaborators

About us

BioSpark

BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。

BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.

Follow us on Twitter: 
https://twitter.com/BioSpark_Group

Follow us on LinkedIn: 
https://www.linkedin.com/company/biospark-group

BioSpark events Calendar: 
https://tinyurl.com/tcwy44t6

Email us: [e-mail]

合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group

 赞 助  机   构 

 战 略  合   作 

BioSpark Group致力于建立华人在生物医领域的生态系统和互助网络，立足于波士顿，我们在硅谷和中国与LEAP Initiative、Dahshu和医药笔记达成战略合作。

更多精彩，请关注BioSpark公众号